

BTK and *PLCG2* remain unmutated in one-third of patients with CLL relapsing on ibrutinib

Silvia Bonfiglio,^{1,2,*} Lesley-Ann Sutton,^{3,*} Viktor Ljungström,^{3,4,*} Antonella Capasso,⁵ Tatjana Pandzic,⁴ Simone Weström,⁴ Hassan Foroughi-Asl,³ Aron Skafason,³ Anna Gellerbring,^{6,7} Anna Lyander,⁶⁻⁸ Francesca Gandini,^{2,9} Gianluca Gaidano,¹⁰ Livio Trentin,¹¹ Lisa Bonello,^{12,13} Gianluigi Reda,¹⁴ Csaba Bödör,^{15,16} Niki Stavroyianni,¹⁷ Constantine S. Tam,^{18,19} Roberto Marasca,²⁰ Francesco Forconi,^{21,22} Panayiotis Panayiotidis,²³ Ingo Ringshausen,²⁴ Ozren Jaksic,²⁵ Anna Maria Frustaci,²⁶ Sunil Iyengar,²⁷ Marta Coscia,^{13,28} Stephen P. Mulligan,²⁹ Loïc Ysebaert,³⁰ Vladimir Strugov,³¹ Carolina Pavlovsky,³² Renata Walewska,³³ Anders Österborg,³⁴ Diego Cortese,³ Pamela Ranghetti,² Panayiotis Baliakas,⁴ Kostas Stamatopoulos,³⁵ Lydia Scarfò,^{2,5,9,†} Richard Rosenquist,^{3,36,†} and Paolo Ghia^{2,5,9,†}

¹Centre for Omics Sciences, IRCCS Ospedale San Raffaele, Milan, Italy; ²Division of Experimental Oncology, B cell Neoplasia Unit, IRCCS Ospedale San Raffaele, Milan, Italy; ³Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; ⁴Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden; ⁵Strategic Research Program on CLL, IRCCS Ospedale San Raffaele, Milan, Italy; ⁶Clinical Genomics Stockholm, Science for Life Laboratory, Solna, Sweden; ⁷Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden; ⁸School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm, Sweden; ⁹Università Vita-Salute San Raffaele, Milan, Italy; ¹⁰Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy; ¹¹Department of Medicine, Hematology and Clinical Immunology, University of Padua, Italy; ¹²Molecular Pathology Unit, A.O.U. Città della Salute e della Scienza, Torino, Italy; ¹³Department of Molecular Biotechnologies and Health Sciences, Università di Torino, Italy; ¹⁴Department of Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ¹⁵HCEMM-SU Molecular Oncohematology Research Group, Budapest, Hungary; ¹⁶1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary; ¹⁷Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece; ¹⁸Department of Hematology, Alfred Health, Melbourne, Victoria, Australia; ¹⁹Central Clinical School, Monash University, Melbourne, Victoria, Australia; ²⁰Department of Medical and Surgical Sciences, Hematology Unit, University of Modena and Reggio Emilia, Modena, Italy; ²¹School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; ²²Department of Hematology, University Hospital National Health Service Trust, Southampton, United Kingdom; ²³Department of Propædeutic Internal Medicine, Laiko Hospital, University of Athens, Athens, Greece; ²⁴Department of Hematology, University of Cambridge, Cambridge, United Kingdom; ²⁵Dubrava University Hospital, Zagreb, Croatia; ²⁶Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy; ²⁷Department of Haemato-Oncology, Royal Marsden Hospital, London, United Kingdom; ²⁸Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy; ²⁹Department of Haematology, Royal North Shore Hospital, University of Sydney, Sydney, Australia; ³⁰Département d'Hématologie, Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse, France; ³¹Almazov National Medical Research Centre, St Petersburg, Russia; ³²FUNDALEU, Clinical Research Center, Buenos Aires, Argentina; ³³Department of Molecular Pathology, University Hospitals Dorset, Bournemouth, United Kingdom; ³⁴Department of Hematology, Karolinska University Hospital, Stockholm, Sweden; ³⁵Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece; and ³⁶Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden

Key Points

- One-third of patients with CLL relapsing on ibrutinib do not carry *BTK/PLCG2* mutations, even with a 0.1% sensitivity.
- Additional mechanisms, such as del(8p), *EGR2* and NF-κB pathway mutations, may be cooperating in determining progression on ibrutinib.

Patients with chronic lymphocytic leukemia (CLL) progressing on ibrutinib constitute an unmet need. Though Bruton tyrosine kinase (*BTK*) and *PLCG2* mutations are associated with ibrutinib resistance, their frequency and relevance to progression are not fully understood. In this multicenter retrospective observational study, we analyzed 98 patients with CLL on ibrutinib (49 relapsing after an initial response and 49 still responding after ≥ 1 year of continuous treatment) using a next-generation sequencing (NGS) panel (1% sensitivity) comprising 13 CLL-relevant genes including *BTK* and *PLCG2*. *BTK* hotspot mutations were validated by droplet digital polymerase chain reaction (ddPCR) (0.1% sensitivity). By integrating NGS and ddPCR results, 32 of 49 relapsing cases (65%) carried at least 1 hotspot *BTK* and/or *PLCG2* mutation(s); in 6 of 32, *BTK* mutations were only detected by ddPCR (variant allele frequency [VAF] 0.1% to 1.2%). *BTK/PLCG2* mutations were also identified in 6 of 49 responding patients (12%; 5/6 VAF <10%), of whom 2 progressed later. Among the relapsing patients, the *BTK*-mutated (*BTK*^{mut}) group was enriched for *EGR2* mutations, whereas *BTK*-wildtype (*BTK*^{wild}) cases more frequently displayed *BIRC3* and *NFKBIE* mutations. Using an extended capture-based panel, only *BRAF* and *IKZF3* mutations

Submitted 24 August 2022; accepted 1 January 2023; prepublished online on *Blood Advances* First Edition 25 January 2023; final version published online 16 June 2023. <https://doi.org/10.1182/bloodadvances.2022008821>.

*S.B., L.-A.S., and V.L. are the joint first authors.

†L.S., R.R., and P.G. are the joint last authors.

NGS data for HaloPlex (fastq files) have been deposited to the European nucleotide archive, <https://www.ebi.ac.uk/ena/> (accession ID PRJEB44894), whereas the

lymphoid panel NGS data (CRAM files) are available via Figshare at <https://doi.org/10.17044/scilifelab.19721998>.

The online version of this article contains a data supplement.

© 2023 by The American Society of Hematology. Licensed under [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International \(CC BY-NC-ND 4.0\)](https://creativecommons.org/licenses/by-nc-nd/4.0/), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

showed a predominance in relapsing cases, who were enriched for del(8p) (n = 11; 3 *BTK*^{wt}). Finally, no difference in *TP53* mutation burden was observed between *BTK*^{mut} and *BTK*^{wt} relapsing cases, and ibrutinib treatment did not favor selection of *TP53*-aberrant clones. In conclusion, we show that *BTK/PLCG2* mutations were absent in a substantial fraction (35%) of a real-world cohort failing ibrutinib, and propose additional mechanisms contributing to resistance.

Introduction

The first-in-class Bruton tyrosine kinase (BTK) inhibitor ibrutinib covalently binds to BTK,^{1,2,3} and has demonstrated efficacy in both treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL).⁴⁻⁷ Although the majority of patients with CLL obtain long-lasting responses, the following 3 main reasons for ibrutinib discontinuation have emerged: intolerance (~25% of patients), and, particularly among relapsed/refractory patients, Richter transformation (10%), and CLL progression (~20%).^{8,9} Several studies have identified *BTK* and/or *PLCG2* gene mutations in the majority (up to 100%) of patients with CLL relapsing on ibrutinib,¹⁰⁻¹³ even several months before clinical relapse.^{10,13} Mutations preferentially occurred at the cysteine 481 residue resulting in the replacement of cysteine by serine (p.C481S) or arginine (p.C481R). Mutations at this site lead to abrogation of the covalent binding of ibrutinib, with only transient inhibition of the mutant protein.^{10,11} In contrast, multiple, though less frequent, mutations within the downstream signaling molecule *PLCG2* usually result in a gain-of-function, promoting B cell receptor (BcR) signaling despite BTK inhibition.^{10,11,14} Additional mechanisms of resistance to ibrutinib have been proposed such as the loss of TRAIL-R expression because of del(8p),¹⁵⁻¹⁷ whereas mutations of individual genes (eg, *EIF2AK3*, *EP300*, *KMT2D*)¹⁵ have been occasionally reported.

The proportion of CLL cells carrying mutations within the *BTK/PLCG2* genes varies considerably, with some cases showing a very low clonal burden, hence challenging their proposed contribution to resistance.¹⁸ Thus, a comprehensive understanding of the prevalence and relevance of these mutations in relation to response to ibrutinib will help better refine the mechanisms driving resistance and identify other potential key driver mutations or pathways. In particular, it remains to be established whether these mutations also occur in patients who continue to respond to ibrutinib. Insight into these issues may aid in the validation of predictors of relapse to assist treatment decisions, and in the design of novel treatment modalities to ultimately prevent relapse and disease progression.

To this end, we designed a multicenter international retrospective study, coordinated by the European research initiative on CLL (ERIC), aimed at investigating, in a “real-world” setting, the presence of recurrent gene mutations in *BTK/PLCG2* and other genes of interest by targeted next-generation sequencing (NGS) in patients with CLL failing ibrutinib, and in a cohort of patients who have maintained a response to ibrutinib and remain on therapy for at least 12 months after ibrutinib initiation.

Methods

Patient enrollment and sample collection

Ninety-eight patients with CLL treated with ibrutinib from 21 institutions were included and assigned to 1 of the 2 following groups: relapsed (n = 49; patients progressing after an initial response) and responders (n = 49; patients who maintained a response to ibrutinib for ≥1 year) (Table 1). Patients in both groups received full-dose ibrutinib without >14 days interruption. Progression and response were defined according to the international workshop on CLL 2008 criteria¹⁹; primary refractory cases and patients with Richter transformation were excluded. Paired samples at baseline (at the time of treatment initiation) and progression or ≥1 year after therapy initiation, were available for 50 patients (19 relapsed and 31 responders). Informed consent was obtained in accordance with the declaration of Helsinki and ethical approval was granted by local review committees.

A total of 151 samples were analyzed, obtained from peripheral blood mononuclear cells (PBMC) (n = 143), bone marrow (BM) (n = 7) and 1 baseline sample derived from formalin-fixed paraffin-embedded lymph node tissue. For 3 patients, both BM and PBMC samples obtained at relapse were analyzed.

The fraction of tumor cells by flow cytometry was ≥80% in 79% of all samples in the study. B cells were purified from peripheral blood using a negative-selection immunodensity method (RosetteSep Human B Cells, StemCell Technologies) or from viable frozen PBMCs using a positive-selection method (>95% purity) (EasySep Human CD19 Positive Selection Kit II, StemCell Technologies).

Genomic DNA (gDNA) was extracted using Maxwell 16 Blood DNA Purification kit (Promega) for samples with >1×10⁶ cells; QIAamp DNA Micro kit (Qiagen) for cases with cells numbers ranging from 5 × 10⁴ to 1 × 10⁶; NucleoSpin Tissue XS kit (Macherey-Nagel) for cases with <5 × 10⁴ cells. The gDNA concentration was determined using Qubit (ThermoFisher) and integrity was assessed on Agilent 4200 TapeStation (Agilent Technologies).

NGS

HaloPlex panel: a previously published custom Agilent HaloPlex high sensitivity panel design²⁰ was modified using the Agilent SureDesign software (<https://earray.chem.agilent.com/suredesign/>). The custom probes were designed to target the coding exons or hotspot regions of 13 genes of interest in CLL (*ATM*, *BIRC3*, *BTK*, *EGR2*, *FBXW7*, *MYD88*, *NFKBIE*, *NOTCH1*, *PLCG2*, *POT1*, *SF3B1*, *TP53*, and *XPO1*) (supplemental Table 1). Libraries were prepared using 50 ng of high-quality gDNA input, following the

Table 1. Clinical characteristics of patients included in the study

Characteristics	Relapsed cases (n = 49)	Responders (n = 49)	Entire cohort (n = 98)	P value
Median age, y (range)	66 (33-86)	68 (46-85)	67 (33-86)	ns
Male:female	32:17	31:18	63:35	ns
Median number of previous therapies	2	1	2	ns
Unmutated IGHV, n (%)	28/35 (80)	29/41 (70.7)	57/76 (75)	ns
del(11q), n (%)	14/45 (31)	10/44 (22.7)	24/89 (26.9)	ns
del(17p), n (%)	21/46 (45.6)	21/46 (45.6)	42/92 (45.6)	ns
TP53 mutation, n (%)	13/27 (48.1)	8/38 (21)	21/65 (32.3)	.03
TP53 aberrations (del(17p) and/or TP53 mutations), n (%)	25/46 (54.3)	23/46 (50)	48/92 (52.2)	ns
Best response to ibrutinib				
PR/PR-L	44/49	35/49	79/98	ns
CR	5/49	14/49	19/98	ns
Median duration of ibrutinib treatment, (range) (mo)	36 (6-68)	44 (18-87)	40 (6-87)	ns
Follow-up				
Median follow-up, (range) (mo)	43 (8-84)	46 (18-87)	44 (8-87)	ns
Median overall survival, (95% CI) (mo)	58 (36-80)	NR	NR	$P < .001$
Dead, n (%)	25 (51)	5 (10.2)	30 (30.6)	$P < .001$

CI, confidence interval; CR, complete response; ns, not significant; NR, not reached PR, partial response; PR-L, partial response with lymphocytosis.

manufacturer's instructions. Paired-end sequencing (150 bp reads) was performed on a NextSeq instrument (Illumina, Hayward, CA).

Lymphoid panel: DNA samples were analyzed using a custom-designed, capture-based gene panel, GMS Lymphoid panel (Twist Bioscience), including 252 genes, selected based on their relevance in lymphoid malignancies.^{21,22} The panel also included genome-wide backbone probes for copy-number analysis. Library preparation and sequencing were performed as described in supplemental Data.

Bioinformatics analysis

HaloPlex panel (refer to supplemental Data): FASTQ files were preprocessed by Agilent SureCallTrimmer (v4.0.1), aligned to the GRCh37 human reference genome using bwa-mem (v0.7.16) and postprocessed using Samtools (v1.8). The Agilent LocatIt tool (v4.0.1) was applied for processing of molecular barcode information. PISCES (v5.2.10.49) was used for detection of single nucleotide variants and small insertions/deletions (indels) (1% VAF). Variants were annotated with population variation databases and Cosmic (v85) using VEP²³ (v91) and SnpEFF (v4.3). Pysamstats (v1.1.2) was used for detailed investigation of mutations at codon 481 of the *BTK* gene and at selected *PLCG2* hotspots ("per base" analysis).

Lymphoid panel: BALSAMIC²⁴ was applied to analyze the FASTQ files and for somatic variant calling (10% VAF) and copy-number aberration detection, as described in supplemental Data.

Droplet digital polymerase chain reaction (ddPCR)

One hundred sixteen samples included in the HaloPlex analysis were analyzed with ddPCR with a sensitivity of 0.1% at the *BTK*

hotspot C481S (c.1442G>C and c.1441T>A), according to the manufacturer's instructions, using Bio-Rad reagents and equipments (refer to supplemental Data).

Statistical analysis

Continuous variables were analyzed using the median and range (minimum, maximum). Categorical variables are presented as percentage of total number of patients with available information. Correlation of variables with disease outcome were evaluated in univariate analysis with nonparametric tests (Chi-square and Fisher Exact test in case of categorical variables, Mann-Whitney and Kruskal-Wallis test in case of continuous variables). Time-to-progression (TTP, time between ibrutinib initiation and documented progression or last follow-up) and overall survival (time between ibrutinib initiation and last follow-up or date of death) were estimated using the Kaplan-Meier Product Limit estimator and log-rank test.

Results

Patient clinical characteristics

Characteristics of the 98 eligible patients are described in Table 1. The study population was enriched for patients with high-risk features consistent with a heavily pretreated population (median number of previous therapies 2; range, 1-6), with only 17 patients receiving ibrutinib as first-line treatment (13 responders; 4 relapsed). No significant differences between relapsed and responders subgroups were identified, except for a higher percentage of TP53 mutations in relapsed cases (48% vs 21%, $P = .03$). All patients obtained at least a partial response with lymphocytosis (PR-L) on ibrutinib, with those in the relapsed group

progressing after a median of 34 months (range, 5-66). The median duration of treatment was 44 months (range, 18-87) in the responders and 36 months (range, 6-68) in the relapsed cases.

Detection of hotspot *BTK* and *PLCG2* mutations by HaloPlex NGS analysis and validation by ddPCR

By applying our standardized bioinformatics pipeline (1% sensitivity), a total of 38 hotspot *BTK* mutations were detected in 24 of 49 relapsed patients (49%), with 7 of 24 (29%) carrying ≥ 2 hotspot *BTK* mutations (Table 2). The VAF of the individual *BTK* mutations differed considerably (range, 1.8%-79.5%; median, 16.8%; not sex-normalized). In 6 of 24 patients (25%), *BTK* mutations were present at low-VAF only (<10%), whereas in 4 of 24 patients (16.7%), low- and high-VAF *BTK* mutations co-occurred (Table 2).

Samples from 47 of 49 relapsed patients (95.9%) were analyzed by ddPCR targeting *BTK* hotspot mutations as well. This analysis confirmed all NGS-detected *BTK* p.C481S mutation(s), with both tests reporting similar VAFs for the majority of mutations (Table 2). Discrepancies were observed in 3 patients (#1, #2, #24), who harbored a p.C481S mutation stemming from 2 different nucleotide substitutions (c.1441T>A and c.1442G>C) with very different VAFs, thus the discordance likely being the result of cross-reactivity in the ddPCR assays because of the strong positivity of the major clone.

The ddPCR assay identified additional *BTK* p.C481S low-VAF mutations (range, 0.1%-2.4%) in 16 relapsed patients (Table 2). Ten of them carried also a major *BTK*-mutated clone identified by both standard NGS and ddPCR analysis and hence were already classed as *BTK* mutated; in 5 of 11 of these samples the additional *BTK* mutation(s) were confirmed by per base NGS reanalysis (Table 2). In the remaining 6 patients, wildtype by standard NGS analysis (1% sensitivity), the ddPCR assay identified low-VAF *BTK* mutations (range, 0.1%-1.2%; 5/6 <1%), which were confirmed by per base NGS reanalysis in 4 of 6 samples. In addition, in 1 of these patients (#29), 2 additional low-VAF mutations were retrieved by per base NGS analysis only (Table 2). Samples from BM and peripheral blood at the time of relapse were available for 3 patients (#7, #15 and #20). The *BTK* p.C481S mutation was found in both the BM and PBMC sample from all 3 cases (Table 2), with a higher VAF detected in the PBMC in case #7 and #15, and with similarly low levels in patient #20, though only detected by either per base NGS analysis or ddPCR in the PBMC sample.

A per base NGS reanalysis was performed for *PLCG2* gene as well at selected hotspots, to detect mutations with VAF <1%. Twelve relapsed patients harboring *BTK* mutation(s) also carried hotspot *PLCG2* mutation(s). In 4 of them (#3, #6, #10 and #20), carrying *BTK* mutations at low-VAF only (<10%), multiple *PLCG2* mutations with VAFs in the range of 0.2% to 32.7% were present (Table 2). Among the 25 of 49 relapsed patients (51%) negative for *BTK* mutations, only 2 cases (#2 and #26) carried hotspot *PLCG2* mutations (Table 2).

Taking all analyzes together, 65% of relapsed patients carried at least 1 hotspot mutation in *BTK* and/or *PLCG2*, with 12 of 30 (40%) carrying *BTK*-mutated clone(s) at a VAF <10%, of which 6 at a VAF $\leq 1.2\%$ (Table 2). No hotspot mutations in *BTK* or *PLCG2* were detected in any of the matched baseline samples.

Only 3 of 49 responders (#33, #34 and #35) carried the *BTK* p.C481S substitution at varying allelic frequencies (19.5%, 4.4% and 2.7%, respectively). Two of them (#33 and #34), progressed 6 and 15 months after sampling, respectively, and were also found to harbor *PLCG2* hotspots mutations at low VAFs (Table 2). The third patient (#35) remained in response at last follow-up (10 months after sampling) and carried no detectable *PLCG2* mutation.

All *BTK* mutations detected by NGS in the 3 responsive patients were confirmed by ddPCR at similar VAFs. In patient #34, the ddPCR assay detected an additional *BTK*-mutated (*BTK*^{mut}) minor subclone (VAF 0.2%) not confirmed by the NGS per base reanalysis; however, another small subclone (VAF 0.7%) was detected by the NGS per base reanalysis (Table 2).

In addition, samples at time point ≥ 1 year for 43 of 46 responders, wildtype for *BTK* as assessed by standard NGS analysis, were also analyzed by ddPCR. In 3 of 43 patients (#36, #37, #38) a p.C481S mutation was found at very low VAF (0.4%-1.2%) (Table 2) and was not detected by the NGS per base reanalysis. These 3 patients have maintained a response to ibrutinib at 26, 31 and 33 months after sampling.

Taking all analyzes together, 6 of 49 responders (12%) carried a hotspot mutation in *BTK/PLCG2*, with 5 of 6 cases (83%) harboring *BTK* mutations at a VAF <10%.

Finally, 9 mutations with a VAF <10% and lying outside the known hotspot regions within *BTK* (n = 4) and *PLCG2* (n = 5) were detected, the majority of which had not been reported previously (Table 3). Six of them were found in 5 relapsed patients, all of whom harbored a hotspot mutation in *BTK/PLCG2* genes (Table 3), whereas 3 were observed in responders, with 2 of them having no detectable hotspot mutation (Table 3).

Mutational profiling of the relapsed and responsive cohort

We next investigated the frequency of mutations within the 11 additional genes included in the HaloPlex panel. A total of 415 somatic mutations were detected; no significant difference in the average number of mutations per case in the relapsed vs responsive cohort was observed (4.6 vs 3.9, respectively). The VAF range spanned from 1.4% to 100%, however, half of all variants were found at allelic frequencies <10% (203/415; 48.9%) (supplemental Table 2).

Aside from mutations in *BTK* and *PLCG2*, the most frequently mutated genes in the relapsed patients at progression were: *TP53* (29/49, 59%), *ATM* (14/49, 29%), *EGR2* (10/49, 20%), *SF3B1* (9/49, 18%), *NOTCH1* (8/49, 16%) and *BIRC3* (6/49, 12%), and in the responsive patients at ≥ 1 year sampling after therapy initiation: *TP53* (22/49, 45%), *ATM* (12/49, 24%), *BIRC3* (7/49, 14%), *SF3B1* (6/49, 12%) and *NOTCH1* (6/49, 12%) (Figure 1). Two relapsed and 9 responsive patients (without *BTK/PLCG2* mutations) did not carry mutations in any genes tested. Combining FISH and mutational data, 32 of 49 of the relapsed patients (65%) displayed *TP53* aberrations compared with that of 28 of 49 of the responsive patients (57%). Along the same lines, 19 of 49 patients (39%) in the relapsed cohort carried an *ATM* alteration (mutation and/or deletion) vs 21 of 49 (43%) in the responsive cohort.

Table 2. BTK and PLCG2 hotspot mutations in relapsed and responsive cohorts, assessed by both HaloPlex NGS and ddPCR analysis

Patient ID	Cohort	% CD19+ in sample	BTK hotspot mutations					PLCG2 hotspot mutations				
			Coding DNA description	Protein description	Standard NGS VAF (%)	Per base NGS VAF (%)	ddPCR VAF (%)	Coding DNA description	Protein description	Standard NGS VAF (%)	Per base NGS VAF (%)	Time on ibrutinib at sampling (months)
1	Relapsed	99	c.1442G>C	p.C481S	79.5	79.5	85.0	c.3418G>A	p.D1140N	3.9	3.9	46
			c.1441T>A	p.C481S	2.6	2.6	11					
			c.1442G>A	p.C481Y	ND	0.5	not tested					
			c.1441T>C	p.C481R	ND	0.3	not tested	c.2977G>T	p.D993Y	ND	0.9	
							c.3422T>A	p.M1141K	ND	0.4		
2	Relapsed	>90	c.1441T>A	p.C481S	53.4	53.7	65	c.2978A>G	p.D993G	7.9	7.8	12
			c.1442G>C	p.C481S	12.8	12.8	30.7	c.2977G>T	p.D993Y	4.8	4.8	
3	Relapsed	85	c.1442G>C	p.C481S	2.7	2.7	2.8	c.3418G>A	p.D1140N	ND	0.4	36
			c.1441T>A	p.C481S	2.4	2.5	2.2	c.3422T>G	p.M1141R	ND	0.3	
4	Relapsed	unknown	c.1441T>C	p.C481R	40.3	40.1	not tested	None	None	NA	NA	17
5	Relapsed	>90	c.1442G>C	p.C481S	32.0	32.0	32.7	None	None	NA	NA	47
			c.1441T>A	p.C481S	ND	ND	0.9					
6	Relapsed	unknown	c.1442G>C	p.C481S	6.1	6.1	7.1	c.3412_3414del	p.1138_1138del	13.0	13.0	11
			c.1441T>A	p.C481S	ND	ND	0.5	c.2543T>G	p.L848R	9.3	9.3	
								c.3422T>A	p.M1141K	2.0	2.0	
								c.3418G>A	p.D1140N	ND	1.0	
							c.3422T>G	p.M1141R	ND	1.7		
7-BM	Relapsed	>95	c.1442G>C	p.C481S	7.1	7.1	8.0	c.2978A>G	p.D993G	ND	0.8	9
7-PBMC		>95	c.1442G>C	p.C481S	23.3	23.3	18.2	c.2978A>G	p.D993G	ND	1.3	
8	Relapsed	>95	c.1442G>C	p.C481S	31.2	31.2	29.6	c.3422T>G	p.M1141R	4.0	4.0	15
			c.1441T>A	p.C481S	ND	ND	0.3					
9	Relapsed	85	c.1442G>C	p.C481S	33.2	33.2	35.6	None	None	NA	NA	43
10	Relapsed	95	c.1442G>C	p.C481S	7.8	7.8	10.0	c.2977G>T	p.D993Y	32.7	32.7	40
			c.1441T>A	p.C481S	ND	ND	inconclusive	c.2977G>C	p.D993H	2.0	2.0	
								c.2978A>G	p.D993G	ND	1.3	
							c.3418G>A	p.D1140N	ND	0.6		
11	Relapsed	95	c.1442G>C	p.C481S	42.7	42.8	41.6	c.2535A>T	p.L845F	ND	0.8	43
			c.1441T>A	p.C481S	ND	0.8	2.2	c.2977G>C	p.D993H	ND	0.7	
12	Relapsed	94	c.1442G>C	p.C481S	62.5	62.5	62.7	c.2977G>C	p.D993H	ND	0.2	16
13	Relapsed	90	c.1442G>C	p.C481S	17.9	17.9	18.0	None	None	NA	NA	32
			c.1441T>A	p.C481S	ND	ND	0.2					
14	Relapsed	85	c.1442G>C	p.C481S	5.8	5.8	6.8	None	None	NA	NA	41
			c.1441T>A	p.C481S	ND	0.7	1.0					
15-PBMC	Relapsed	70	c.1442G>C	p.C481S	41.9	41.8	43.8	c.2535A>C	p.L845F	NA	0.7	37
			c.1441T>A	p.C481S	ND	0.5	0.7	c.2535A>T	p.L845F	NA	0.7	

BTK hotspots VAFs were not sex-normalized.
 ND, not detected; NA, not available.

Table 2 (continued)

Patient ID	Cohort	% CD19+ in sample	BTK hotspot mutations					PLCG2 hotspot mutations						
			Coding DNA description	Protein description	Standard NGS VAF (%)	Per base NGS VAF (%)	ddPCR VAF (%)	Coding DNA description	Protein description	Standard NGS VAF (%)	Per base NGS VAF (%)	Time on ibrutinib at sampling (months)		
15-BM		38	c.1442G>C	p.C481S	11.5	11.5	13.2	None	None	NA	NA			
			c.1441T>A	p.C481S	ND	ND	0.1							
16	Relapsed	35	c.1442G>C	p.C481S	3.0	3.0	not tested	None	None	NA	NA	56		
17	Relapsed	unknown	c.1442G>C	p.C481S	61.6	61.5	66.3	None	None	NA	NA	42		
			c.1441T>A	p.C481S	ND	ND	0.3							
			c.1442G>A	p.C481Y	ND	0.5	not tested							
18	Relapsed	99	c.1442G>C	p.C481S	15.7	15.7	17.2	c.2535A>T	p.L845F	NA	0.3	62		
			c.1441T>A	p.C481S	ND	0.1	0.2							
			c.1442G>A	p.C481Y	ND	1.4	not tested							
19	Relapsed	unknown	c.1441T>A	p.C481S	37.9	37.9	50.3	None	None	NA	NA	34		
			c.1442G>C	p.C481S	23.4	23.4	39.2							
20-BM	Relapsed	66	c.1442G>C	p.C481S	2.3	2.3	2.2	c.3412_3414del	p.1138_1138del	2.7	2.7	34		
								c.2535A>C	p.L845F	3.4	3.4			
								c.2535A>T	p.L845F	2.7	2.6			
						c.1442G>A	p.C481Y	ND	0.2	not tested	c.2977G>C	p.D993H	1.7	1.7
										c.1993C>T	p.R665W	ND	0.8	
										c.2120C>T	p.S707F	ND	0.3	
										c.3418G>A	p.D1140N	ND	0.7	
										c.3422T>A	p.M1141K	ND	0.7	
20-PBMC		92	c.1442G>C	p.C481S	ND	1.4	1.8	c.3412_3414del	p.1138_1138del	12.7	12.7			
								c.2535A>C	p.L845F	2.5	2.5			
								c.2535A>T	p.L845F	2.0	2.0			
								c.2977G>C	p.D993H	1.8	1.8			
								c.1993C>T	p.R665W	ND	0.9			
								c.3418G>A	p.D1140N	ND	0.4			
								c.3422T>A	p.M1141K	ND	0.6			
								c.3422T>G	p.M1141R	ND	0.6			
21	Relapsed	unknown	c.1441T>C	p.C481R	51.8	51.7	not tested	None	None	NA	NA	42		
			c.1442G>C	p.C481S	5.5	5.5	7.2							
			c.1441T>A	p.C481S	1.8	1.8	2.7							
			c.1442G>A	p.C481Y	2.8	2.8	not tested							
22	Relapsed	73	c.1443C>A	p.C481	2.2	2.2	not tested							
			c.1442G>T	p.C481F	33.5	33.5	not tested	None	None	NA	NA	38		
			c.1442G>C	p.C481S	4.8	4.8	8.6							

BTK hotspots VAFs were not sex-normalized.
 ND, not detected; NA, not available.

Table 2 (continued)

Patient ID	Cohort	% CD19+ in sample	BTK hotspot mutations					PLCG2 hotspot mutations				Time on ibrutinib at sampling (months)					
			Coding DNA description	Protein description	Standard NGS VAF (%)	Per base NGS VAF (%)	ddPCR VAF (%)	Coding DNA description	Protein description	Standard NGS VAF (%)	Per base NGS VAF (%)						
23	Relapsed	81	c.1442G>C	p.C481S	79.3	79.3	79.9	None	None	NA	NA	37					
			c.1441T>A	p.C481S	ND	0.4	2.4										
24	Relapsed	97	c.1441T>A	p.C481S	47.8	47.8	69.2	None	None	NA	NA	37					
			c.1442G>C	p.C481S	22	22	57.9										
			c.1442G>A	p.C481Y	4.8	4.8	not tested										
			c.1442G>T	p.C481F	4.6	4.6	not tested										
25	Relapsed	unknown	None	None	NA	NA	NA	c.2120C>T	p.S707F	21.2	21.2	42					
								c.3412_3414del	p.1138_1138del	ND	0.2						
26	Relapsed	75	None	None	NA	NA	NA	c.3416A>G	p.E1139G	3	3.2	10					
27	Relapsed	74	c.1442G>C	p.C481S	ND	1.2	0.8	None	None	NA	NA	5					
28	Relapsed	18	c.1442G>C	p.C481S	ND	0.3	0.1	None	None	NA	NA	43					
29	Relapsed	unknown	c.1441T>A	p.C481S	ND	0.9	1.2	None	None	NA	NA	33					
			c.1442G>C	p.C481S	ND	1.5	ND										
			c.1441T>C	p.C481R	ND	1.3	not tested										
30	Relapsed	75	c.1442G>C	p.C481S	ND	0.1	0.1	None	None	NA	NA	45					
31	Relapsed	81	c.1442G>C	p.C481S	ND	ND	0.2	None	None	NA	NA	56					
32	Relapsed	99	c.1442G>C	p.C481S	ND	ND	0.1	None	None	NA	NA	56					
33	Responsive	unknown	c.1442G>C	p.C481S	19.5	19.5	18.7	c.2977G>C	p.D993H	2.9	2.9	32					
								c.2535A>C	p.L845F	ND	1.4						
								c.3419A>G	p.D1140G	ND	0.4						
34	Responsive	unknown	c.1442G>C	p.C481S	4.4	4.4	5.4	c.3419A>G	p.D1140G	5.5	5.5	40					
								c.2535A>T	p.L845F	3.4	2.7						
								c.1442G>A	p.C481Y	ND	0.7		not tested	c.2535A>C	p.L845F	2.7	2.1
								c.1441T>A	p.C481S	ND	ND		0.2				
35	Responsive	98	c.1442G>C	p.C481S	2.7	2.7	2.7	None	None	NA	NA	28					
36	Responsive	88	c.1442G>C	p.C481S	ND	ND	0.4	None	None	NA	NA	18					
37	Responsive	89	c.1442G>C	p.C481S	ND	ND	1.2	None	None	NA	NA	37					
38	Responsive	89	c.1442G>C	p.C481S	ND	ND	0.7	None	None	NA	NA	20					

BTK hotspots VAFs were not sex-normalized.
 ND, not detected; NA, not available.

Table 3. BTK and PLCG2 nonhotspot mutations in relapsed and responsive cohorts, as assessed by targeted NGS analysis

Patient ID	Cohort	Time point	Gene	coding DNA description	protein description	protein domain	NGS VAF (%)	References	Other BTK hotspot mutations	Other PLCG2 hotspot mutations
18	Relapsed	relapse	BTK	c.136C>T	p.R46C	PH	2.6	none	yes	no
26	Relapsed	relapse	BTK	c.946A>G	p.T316A	SH2	3.0	Sharma et al 2016; Kadri et al 2017; Jones et al 2017	no	yes
				c.1003G>C	p.V335L	SH2	3.6	none		
34	Responsive	≥ 1 y	BTK	c.1283C>A	p.A428D	TK	6.0	Wang et al 2022	yes	yes
7-PBMC	Relapsed	relapse	PLCG2	c.601C>G	p.Q201E	EF	2.7	none	yes	no
1	Relapsed	relapse	PLCG2	c.683T>A	p.F228Y	EF	1.7	none	yes	yes
6	Relapsed	relapse	PLCG2	c.2543T>G	p.L848R	PH	9.3	Landau et al 2017	yes	yes
60	Responsive	≥ 1 y	PLCG2	c.846G>C	p.E282D	EF	3.8	none	no	no
83	Responsive	≥ 1 y	PLCG2	c.3076A>T	p.A1026T	Y	3.2	none	no	no

An asymmetric distribution of mutations in other genes was noted in BTK^{mut} vs BTK^{wt} relapsed patients. Specifically, *EGR2* was mutated in 9 of 24 BTK^{mut} vs 1 of 25 BTK^{wt} patients ($P < .01$), whereas *BIRC3* ($n = 6$; $P < .05$) and *NFKBIE* ($n = 3$, $P > .05$) mutations were only detected in the BTK^{wt} group (Figure 1). In contrast, *TP53* mutation burden was not significantly different between BTK^{mut} and BTK^{wt} relapsed cases.

In 19 relapsed patients, samples at both baseline and relapse were available. The total number of somatic mutations at baseline was 36 (average: 1.9; range, 1-4), compared with that of 60 mutations carried by the matched relapse samples (average: 3.2; range, 0-7), the difference being mainly because of the appearance of *BTK/PLCG2* mutations ($n = 18$). In other words, for all other genes analyzed, only a few patients acquired mutations at the relapse vs the baseline time point, including 2 patients who gained *EGR2* mutations at low allelic burdens (#5 and #30) (supplemental Figure 1; supplemental Figure 2A). Accordingly, *BIRC3* and *NFKBIE* mutated patients carried mutations at both time points, except for patient #41 who was *NFKBIE* mutated only at baseline with a low allelic burden (supplemental Figure 2B,C).

Paired samples (at baseline and at time point ≥ 1 year) were available for 31 patients in the responsive cohort. The total number of somatic mutations at baseline was 70 (average: 2.3; range, 0-10), compared with that of 84 mutations detected at time point ≥ 1 year (average: 2.7; range, 0-11). The frequency of mutated genes in samples at baseline compared with that of at ≥ 1 year time point was not significantly different (supplemental Figure 3).

Additional genetic aberrations assessed by the lymphoid panel

To investigate if additional genetic aberrations may be present in relapsed vs responsive patients, we applied a capture-based lymphoid panel and analyzed the mutational status of the 239 genes not included in the HaloPlex panel and the genome-wide copy-number status in 104 gDNA samples from 72 patients (38/49 relapsed, 34/49 responsive). We detected recurrent mutations in *ASXL1*, *BRAF*, *IKZF3*, *KRAS*, *MED12*, *MGA*, *RPS15*, *SPEN*, and *ZFN292*; however, only *BRAF*, and potentially *IKZF3*, showed a predominance in relapsed cases (supplemental Table 3; supplemental Figure 4). Considering that occasional patients progressing on ibrutinib^{15,16} have displayed *EIF2AK3*, *EP300*, and *KMT2D* mutations and del(8p), we specifically looked for these aberrations. Only 1 relapsed patient (BTK^{mut} by ddPCR only) carried an *EP300* mutation (VAF 47.9%) at relapse, whereas 2 *KMT2D* mutations (VAF 28.9; 65.7%) were retrieved in 1 relapsed BTK^{wt} patient at relapse. *EIF2AK3* was wildtype in all patients (supplemental Table 3). Finally, del(8p) was detected in 13 patients: 11 relapsed, 4 of them BTK^{wt} by HaloPlex analysis (1 mutated by ddPCR only), and 2 responsive BTK^{wt} patients (supplemental Table 4).

TP53 clonal dynamics under ibrutinib treatment

Among 19 relapsed patients with paired samples, 7 of 19 were *TP53* wildtype at both time points (1 of them BTK^{mut} by HaloPlex analysis) and 12 of 19 carried a *TP53* mutation at some point (7/12 with at least 1 *BTK* hotspot mutation detected by HaloPlex analysis). Among the 12 patients with *TP53* mutation, 3 showed




Figure 1. OncoPrint displaying the somatic variants detected in the 13 genes analyzed by a HaloPlex high sensitivity custom panel in the relapsed and responding cohorts. Illustrated are the distribution of the somatic variants, IGHV mutational status, cytogenetic profile determined by fluorescence in situ hybridization or lymphoid panel (del[8p]), and the mutation frequency of each gene in the relapsed and responding cohorts, respectively. Patient identifiers are indicated across the top row.

expansion ($n = 2$) of an existing clone or the appearance ($n = 1$) of a new clone at relapse; 1 showed a reduction of an existing clone; 5 carried a stable mutant clone, at both time points. One patient carried 3 different *TP53* clones and, interestingly, 1 expanded, 1 reduced and 1 appeared at relapse (Figure 2A). In 2 patients the clonal dynamics could not be reliably analyzed because of missing CD19⁺ purity data.

Among 31 responsive patients with paired samples, 10 were *TP53* wildtype at both time points and 21 of 31 carried at least 1 *TP53* mutation at 1 or both time points. Among the latter, 7 patients showed expansion ($n = 2$) of an existing clone or the appearance ($n = 5$) of 1 or more *TP53* mutations at the time point ≥ 1 year (VAF < 10%); 5 showed a reduction ($n = 1$) or the disappearance ($n = 4$) of existing clones; 4 carried a stable mutant clone, with either high ($n = 1$) or low ($n = 3$) VAF, at both time points (Figure 2B). The remaining 5 patients carried multiple *TP53* mutations at both time points, of which 4 were mainly characterized

by clonal stability or decrease, with the appearance of new clones with VAF < 10% in 2 of them (Figure 2B).

Correlation of NGS data with clinical outcome in relapsed cases

Among relapsed patients, those with *BTK* and/or *PLCG2* hotspot mutations ($n = 32$, assessed by any method) experienced a longer TTP than those without mutations ($n = 17$) (median TTP, 36 months; range, 5-56 vs 14.5 months; range, 5-66, respectively; $P = .053$). Clinical indications of progression on ibrutinib did not differ in the 2 subgroups with the most frequent being the presence of lymphadenopathies (22/32 in the *BTK/PLCG2* mutated vs 9/17 in the *BTK/PLCG2* wildtype cases), followed by anemia and/or thrombocytopenia because of BM infiltration (7/32 vs 3/18), splenomegaly (0/31 vs 3/18) and lymphocyte doubling time (3/31 vs 2/18). After a median follow-up of 43 months (8-84), overall survival in the relapsed cohort was 58 months, without statistically significant difference between the 2 subgroups.




Figure 2. *TP53* clonal dynamics in the relapsed and responsive cohorts. (A) *TP53* clonal dynamics in 10 mutated patients of the relapsed cohort. Each patient is represented by a different color. The vertical axis displays the mutation VAF%, corrected according to the % of CD19⁺ cells in the sample. Two patients were not included in the chart because of missing CD19⁺ purity data. (B) *TP53* clonal dynamics in 18 mutated patients of the responsive cohort. Each patient is represented by a different color. The vertical axis displays the mutation VAF%, corrected according to the % of CD19⁺ cells in the sample. Three patients were not included in the chart because of the missing CD19⁺ purity data.

Discussion

In this study, we performed targeted NGS in a real-world cohort of patients with CLL relapsed on or responsive to ibrutinib treatment, to gain further insights into the mechanisms implicated in the emergence of resistance.

We show that up to 65% of patients relapsing on ibrutinib carried at least 1 hotspot *BTK* mutation at the cysteine 481 residue, and/or ≥ 1 hotspot *PLCG2* mutations, by integrating NGS analysis (1% sensitivity) with more sensitive techniques such as per base NGS analysis and ddPCR (0.1% sensitivity). This prevalence of *BTK/PLCG2* mutations is lower than those reported in most previous studies, where the overall frequency of *BTK* and/or *PLCG2* mutated relapsed patients (1% VAF cutoff) was up to 100%,^{11-13,25} hence indicating the existence of alternative mechanisms of resistance. Similar to other cohorts, we found a large proportion (40%) of relapsed *BTK*-mutated cases harboring hotspot mutation(s) with a VAF <10%, including several cases with VAFs bordering 1%, thus questioning how such clones substantially contribute to resistance. This is further complicated by the finding that, also in the responsive cohort, we detected *BTK* mutations in 6 patients (12%), of whom 3 were with low VAF (0.4%-1.2%). Although 2 of 6 progressed 6 and 15 months after sampling, the others remained in response (3/4 patients <2 years after sampling). For comparison, 6 patients in the relapsed cohort carried similar *BTK* clones at low VAF (0.1%-1.5%) but experienced relapse.

Reasonable assumptions could be that the minor mutant clone may exert a dominant effect on the response of the overall wildtype tumor cell population, as suggested for ibrutinib-resistant patients

with either CLL²⁶ or Waldenström Macroglobulinemia,²⁷ though this would not explain the detection of such mutations in responding patients even after 2 years of follow-up. Alternatively, resistant and mutated cells may reside in a tissue compartment not analyzed or other mechanisms acting independently or cooperatively may exist.

To explore the latter possibility, we characterized our cohort by NGS for other genes associated with disease progression and dismal prognosis.^{25,28} Notably, the frequency of *TP53*-mutated clones in both the relapsed and responsive cohorts did not differ significantly. However, there was a striking difference between the 2 cohorts in terms of clonal size, with the mean VAF% of *TP53* mutant clones being higher in the relapsed vs the responsive cohort, at both baseline (57% vs 19%) and relapse/ ≥ 1 year time point (59% vs 16%), with almost all *TP53* mutations in the relapsed group having a VAF $\geq 10\%$. On the contrary, in the responsive cohort the majority of *TP53* mutations was present at a VAF <10%, at both baseline and at ≥ 1 year time point. That said, it is interesting to note that ibrutinib treatment did not seem to favor the selection of *TP53*-aberrant clones even in the relapsed cohort, in which the majority of clones either remained stable or decreased in size at the time of relapse, similar to the responding cohort. This suggests little if any direct involvement of *TP53* aberrations in the onset of ibrutinib resistance, though the presence of large *TP53*-aberrant clones may give a higher propensity toward clonal evolution because of genomic instability and the occurrence of mutations in other genes or pathways ultimately responsible for drug resistance.

In the relapsed cohort, we detected a biased distribution of other gene mutations in *BTK/PLCG2* mutated vs wildtype subgroups.

Interestingly, the transcription factor *EGR2* was almost exclusively mutated in the *BTK*^{mut} relapsed group. *EGR2* is activated through ERK phosphorylation upon BcR stimulation, thus suggesting that *EGR2* mutations might lead to a constitutively dysregulated BcR signaling,²⁹ cooperating with the existing *BTK/PLCG2* mutations toward ibrutinib resistance.

Conversely, *BIRC3* and *NFKBIE* mutations in the relapsed cohort were exclusively detected in the *BTK*^{wt} vs *BTK*^{mut} group (also at baseline), pointing toward an aberrant activation of the canonical/noncanonical NF- κ B pathway as a potential mechanism leading to earlier progression and drug escape. *BIRC3* aberrations have been suggested as predictive factors for poor response to chemotherapy in patients with CLL.³⁰ Our results potentially extend the role of this gene also in shaping resistance to novel therapies, although in the phase 3 RESONATE study progression-free survival in patients treated with ibrutinib was not affected by baseline *BIRC3* mutational status.³¹ Notably, *BIRC3* and/or *NFKBIE* mutations were present also in a minor proportion (14% and 12%) of the responsive patients, respectively. Longer follow-up will be needed to ascertain if the presence of these mutations may associate with future resistance to ibrutinib treatment.^{8,9}

Additional genomic aberrations, including del(8p) and mutations in *EIF2AK3*, *EP300*, *KMT2D*,^{15,16} have been reported in smaller *BTK*^{wt} patient series. By applying a capture-based panel, we confirmed an enrichment of del(8p) in relapsing cases (11 relapsing vs 2 responsive) but with only 3 of them wildtype for *BTK/PLCG2*. Moreover, although recurrent mutations were seen in some other known CLL driver genes, only *BRAF* and *IKZF3* mutations showed a predominance in relapsed cases. In contrast, no clear predilection of mutations in *EIF2AK3*, *EP300*, and *KMT2D* was observed in relapsing vs responsive cases.

Though the existence of additional genomic aberrations explaining the resistance deserves further studies, it is also intriguing to hypothesize the occurrence of “functional resistance,” in the absence of *BTK/PLCG2* mutations, because of either decreased dependence on proximal BcR signaling or to its bypass through the modulation of the functionality of other non-BcR immune pathways.³² Noteworthy, in a recent study,³³ in patients with CLL progressing on idelalisib treatment, *IGF1R* overexpression was associated with progression in the absence of mutations that could explain resistance, highlighting nongenetic mechanisms as causes of secondary resistance.

In conclusion, although we confirm that *BTK/PLCG2* mutations are present in patients with CLL relapsing on ibrutinib, more than one-third of them do not harbor such mutations even after high sensitivity analyses. We also validate enrichment of del(8p) in relapsing patients, mainly in combination with *BTK* mutations. Importantly, we show that additional genetic mechanisms, in particular aberrant activation of the BcR and NF- κ B pathways, may cooperate in determining progression on ibrutinib in some cases. *BTK/PLCG2* mutations may appear at low frequency and can be identified also in a small fraction of patients responding to ibrutinib for <2 years. As a consequence, though we demonstrate the feasibility of a targeted NGS approach to detect such mutations in real-world, its use should not be applied in routine clinical practice, as currently stated in the international recommendations, till we accumulate enough evidence on how to guide treatment decisions when a mutation in these (or other) genes are detected before clinical progression.

Acknowledgments

This project was supported by Cancer Research UK (ECRIN-M3 accelerator award C42023/A2937). This work was in part supported by an unrestricted grant by Sunesis; Associazione Italiana per la Ricerca sul Cancro–AIRC, Milano, Italy (Investigator Grant #20246 and Special Program on Metastatic Disease–5 per mille #21198); ERA NET TRANSCAN-2 Joint Transnational Call for Proposals: JTC 2014 (project #143 GCH-CLL) and JTC 2016 (project #179 NOVEL), project code (MIS) 5041673; Bando della Ricerca Finalizzata 2018, Ministero della Salute, Roma, Italy (progetto RF-2018-12368231); the Hellenic Precision Medicine Network in Oncology; project ODYSSEAS (Intelligent and Automated Systems for enabling the Design, Simulation and Development of Integrated Processes and Products) implemented under the “Action for the Strategic Development on the Research and Technological Sector,” funded by the Operational Programme “Competitiveness, Entrepreneurship and Innovation” (NSRF 2014-2020) and cofinanced by Greece and the European Union, with grant agreement number MIS 5002462; the Swedish Cancer Society, the Swedish Research Council, the Knut and Alice Wallenberg Foundation, Karolinska Institutet, Karolinska University Hospital, and Radiumhemmets Forskningsfonder, Stockholm; Lion’s Cancer Research Foundation, Uppsala; and EU’s Horizon 2020 research and innovation program under grant 739593. The authors acknowledge Clinical Genomics Uppsala, Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Sweden for providing assistance with droplet digital PCR and analysis. The authors acknowledge ACRF and Peter MacCallum molecular laboratories and the CLL Global Foundation for their support.

Authorship

Contribution: S.B. coordinated sample collection, performed NGS experiments, interpreted data and wrote the manuscript; L.-A.S. performed NGS experiments, interpreted data, and wrote the manuscript; V.L. performed bioinformatics analysis and wrote the manuscript; A.C. analyzed and interpreted clinical data; T.P. and S.W. performed ddPCR experiments and analysis; H.F.-A and A.S. performed bioinformatic analysis on the lymphoid panel data; A.G. and A.L. prepared and sequenced libraries for the lymphoid panel; F.G. interpreted lymphoid panel data and wrote the manuscript; P.R. performed sample purification and DNA extraction; L.S. designed the study, coordinated clinical data collection, analyzed and interpreted clinical data and wrote the manuscript; P.G. and R.R. designed the study, interpreted data and wrote the manuscript; and all authors provided samples and clinical data, and edited and approved the manuscript for submission.

Conflict-of-interest disclosure: G.G. is on the advisory board/speaker’s bureau of Janssen, AbbVie, AstraZeneca, and BeiGene. F.F. received honoraria and/or is on the advisory board of AbbVie, Acerta/AstraZeneca, Janssen-Cilag, and BC platforms. O.J. reports consultancy for AstraZeneca and Eli Lilly, and is on the speaker’s bureau of AbbVie, AstraZeneca, and Johnson & Johnson. R.W. reports meeting sponsorship from AbbVie and Janssen; is on the advisory board of AstraZeneca, Janssen, SecuraBio, and AbbVie; and is on the speaker’s bureau of AbbVie, AstraZeneca, Janssen, and BeiGene. A.O. receives research funding from BeiGene, Janssen, AstraZeneca and Gilead. P.B. received honoraria from

AbbVie, Gilead, and Janssen, and received research funding from Gilead. K.S. received honoraria and/or is on the advisory board of AbbVie, Acerta/AstraZeneca, Gilead, and Janssen, and received research funding from AbbVie, Gilead, and Janssen. L.S. is on the advisory board of AbbVie, AstraZeneca, and Janssen. R.R. received honoraria and/or is an advisory board member in AbbVie, AstraZeneca, Janssen, Illumina and Roche. P.G. received honoraria and/or is on the advisory board of AbbVie, Acerta/AstraZeneca, Adaptive, ArQule/MSD, BeiGene, CelGene/Juno, Gilead, Janssen, Loxo/Lilly, and Sunesis, and received research funding from AbbVie, Gilead, Janssen, Novartis, and Sunesis. The remaining authors declare no competing financial interests.

ORCID profiles: S.B., 0000-0002-4422-1580; F.G., 0000-0001-8930-8295; G.G., 0000-0002-4681-0151; L.T., 0000-0003-1222-6149; C.S.T., 0000-0002-9759-5017; R.M., 0000-0002-6431-6878; F.F., 0000-0002-2211-1831; P.P., 0000-0003-0387-3993; I.R., 0000-0002-7247-311X; A.M.F., 0000-0003-2587-7901; S.J., 0000-0003-4863-4160; M.C., 0000-0003-2123-7675; P.B., 0000-0002-5634-7156; K.S., 0000-0001-8529-640X; L.S., 0000-0002-0844-0989; R.R., 0000-0002-9067-9058; P.G., 0000-0003-3750-7342.

Correspondence: Paolo Ghia, Division of Experimental Oncology, Università Vita Salute San Raffaele, Via Olgettina 58, Milan 20132, Italy; email: ghia.paolo@hsr.it.

References

1. Schiattone L, Ghia P, Scarfo L. The evolving treatment landscape of chronic lymphocytic leukemia. *Curr Opin Oncol*. 2019;31(6):568-573.
2. Herman SEM, Mustafa RZ, Gyamfi JA, et al. Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. *Blood*. 2014;123(21):3286-3295.
3. Herman SEM, Niemann CU, Farooqui M, et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. *Leukemia*. 2014;28(11):2188-2196.
4. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. *N Engl J Med*. 2013;369(1):32-42.
5. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. *N Engl J Med*. 2014;371(3):213-223.
6. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. *N Engl J Med*. 2015;373(25):2425-2437.
7. O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. *Lancet Oncol*. 2014;15(1):48-58.
8. Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. *Blood*. 2015;125(13):2062-2067.
9. Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. *JAMA Oncol*. 2015;1(1):80-87.
10. Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. *N Engl J Med*. 2014;370(24):2286-2294.
11. Ahn IE, Underbayev C, Albitar A, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. *Blood*. 2017;129(11):1469-1479.
12. Woyach JA, Ruppert AS, Guinn D, et al. BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia. *J Clin Oncol*. 2017;35(13):1437-1443.
13. Bődör C, Kotmayer L, László T, et al. Screening and monitoring of the BTK^{C481S} mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy. *Br J Haematol*. 2021;194(2):355-364.
14. Liu TM, Woyach JA, Zhong Y, et al. Hypermorphic mutation of phospholipase C, gamma2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. *Blood*. 2015;126(1):61-68.
15. Burger JA, Landau DA, Taylor-Weiner A, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. *Nat Commun*. 2016;7:11589.
16. Landau DA, Sun C, Rosebrock D, et al. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. *Nat Commun*. 2017;8(1):2185.
17. Kadri S, Lee J, Fitzpatrick C, et al. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. *Blood Adv*. 2017;1(12):715-727.
18. Lampson BL, Brown JR. Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia? *Expert Rev Hematol*. 2018;11(3):185-194.
19. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. *Blood*. 2008;111(12):5446-5456.
20. Agathangelidis A, Ljungstrom V, Scarfo L, et al. Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations. *Haematologica*. 2018;103(5):865-873.

21. Mansouri L, Thorvaldsdottir B, Laidou S, et al. Precision diagnostics in lymphomas—recent developments and future directions. *Semin Cancer Biol.* 2022;84:170-183.
22. Hellström Lindberg E, Cavelier L, Cammenga J, Andersson PO, Fioretos T, Rosenquist R. [Precision diagnostics and therapy in hematological malignancies]. *Lakartidningen.* 2021;118:20186.
23. McLaren W, Gil L, Hunt SE, et al. The ensembl variant effect predictor. *Genome Biol.* 2016;17(1):122.
24. Foroughi-Asl H, Jeggari A, Maqbool K, et al. BALSAMIC: bioinformatic analysis pipeline for somatic mutations in cancer (v8.2.3). *Zenodo.* 2021.
25. Kanagal-Shamanna R, Jain P, Patel KP, et al. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. *Cancer.* 2019;125(4):559-574.
26. Lipsky A, Luan D, Chen S, et al. *Single-cell multi-omics reveals distinct paths to survival of admixed BTKC481 mutant vs. wild-type cells in clinically progressing chronic lymphocytic leukemia.* American Society of Hematology Annual Meeting; 2020.
27. Chen JG, Liu X, Munshi M, et al. BTK(Cys481Ser) drives ibrutinib resistance via ERK1/2 and protects BTK(wild-type) MYD88-mutated cells by a paracrine mechanism. *Blood.* 2018;131(18):2047-2059.
28. Mansouri L, Sutton LA, Ljungstrom V, et al. Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia. *J Exp Med.* 2015;212(6):833-843.
29. Young E, Noerenberg D, Mansouri L, et al. EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia. *Leukemia.* 2017;31(7):1547-1554.
30. Diop F, Moia R, Favini C, et al. Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. *Haematologica.* 2020;105(2):448-456.
31. Byrd JC, Hillmen P, O'Brien S, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. *Blood.* 2019;133(19):2031-2042.
32. Gounari M, Ntoufa S, Gerousi M, et al. Dichotomous toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment. *Leukemia.* 2019;33(4):1030-1051.
33. Tausch E, Ljungström V, Agathangelidis A, et al. Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than MAPK/ERK pathway mutations. *Blood.* 2022;139(22):3340-3344.